Psychiatric Phenotype of the Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in Males: Newly Described Fronto-Subcortical Dementia
J Clin Psychiatry 2006;67(1):87-94
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The authors describe and
quantify the neuropsychiatric symptoms present in a
cohort of males with the fragile X mental retardation 1
(FMR1) premutation allele who have developed fragile X-associated
tremor/ataxia syndrome (FXTAS).
Method: Fourteen male carriers of the
FMR1 premutation who had clinical manifestations
of the FXTAS syndrome and 14 age- and education-matched controls were assessed with the
Neuropsychiatric Inventory (NPI), formal cognitive testing, and genetic analysis.
Results: Males with FXTAS had
significantly higher total NPI scores (p < .004) and
significantly higher scores on the
agitation/aggression (p < .004), depression (p < .004), apathy
(p < .004), disinhibition (p < .004), and irritability
(p < .004) scales, compared with controls. Cognitive
performances on the Mini-Mental State Examination did not correlate with severity of symptoms
on the NPI.
Conclusions: The neuropsychiatric
manifestations of FXTAS, based on this preliminary
report, appear to cluster as a fronto-subcortical
dementia. Clinicians encountering patients with
clinical dementia with motor symptoms suggesting FXTAS should consider genetic testing to
determine whether the patient's dementia syndrome
is secondary to a fragile X premutation carrier